The Next Frontier in Cell Therapy: A Review of Major In Vivo CAR-T Commercial Milestones in 2025
Simnova
Innovative Cell Therapy Product Developer
AstraZeneca
Pharmaceutical Technology Research and Development Provider
EsoBiotec
Developer of Immunocyte Therapy
Oricell Therapeutics
Developer of Tumor Immunocyte Products
Umoja Biopharma
Cancer Treatment Drug Developer
Gilead Sciences
Innovative Drug Developer, Distributor
OrnaExpand Cooperation with Simnova: IncorporateBCMATarget
On January 15, 2025, Orna Therapeutics and Shanghai Simnova Biotechnology Co., Ltd. announced the expansion of their strategic partnership to include BCMA as a designated target for RNA-based therapeutic development. This collaboration combines Orna’s circular RNA (oRNA) technology with Simnova’s expertise in cell therapy to develop an in vivo pan-CAR cell therapy targeting BCMA for the treatment of multiple myeloma. Simnova has obtained the rights for research, development, and commercialization in Greater China. (Source: Orna official website)
AstraZeneca AcquisitionEsoBiotec: Betting on the in vivo lentivirus platform
In March 2025, AstraZeneca announced the acquisition of EsoBiotec for a total consideration of up to $1 billion, including an initial payment of $425 million and potential milestone payments of up to $575 million. EsoBiotec's proprietary ENaBL platform utilizes targeted lentiviral vectors to deliver genetic instructions to specific immune cells via intravenous injection, enabling in vivo cell engineering aimed at avoiding immune cell exhaustion and manufacturing bottlenecks associated with traditional cell therapies. (Source: AstraZeneca official website)
QrigincellTherapeutics andUmoja BiopharmaReach Strategic Cooperation
On May 7, 2025, China's Oricell Therapeutics and Umoja Biopharma of the United States announced a strategic partnership to jointly develop a novel in vivo CAR-T cell therapy. Umoja will contribute its VivoVec™ in vivo gene delivery platform, while Oricell Therapeutics will provide its expertise in antibody discovery and CAR construct design, with the aim of accelerating the development of next-generation therapies. (Source: Sohu)
AbbVie AcquisitionCapstan Therapeutics: Doubling Down on Autoimmune Field
On June 30, 2025, AbbVie signed an agreement to acquire Capstan Therapeutics for up to $2.1 billion in cash. The deal includes Capstan’s lead candidate drug, CPTX2309—a CD19-targeted in vivo CAR-T therapy currently in Phase I clinical trials for the treatment of B-cell-mediated autoimmune diseases. Additionally, AbbVie gains access to Capstan's proprietary targeted lipid nanoparticle (tLNP) delivery platform, designed to engineer cells in vivo via RNA delivery. (Source: AbbVie official website)
KiteAcquisitionInterius BioTherapeutics: Expand in vivoCARPlatform
In August 2025, Kite, a subsidiary of Gilead Sciences, announced the acquisition of Interius BioTherapeutics for $350 million in cash. Interius' in vivo platform achieves durable CAR expression through DNA insertion, designed to generate CAR-T cells in patients with a single intravenous infusion without pre-conditioning chemotherapy. This acquisition will enhance Kite's R&D and manufacturing capabilities in the field of cell therapy. (Source: Interius official website)
BMSAcquisitionOrbital Therapeutics: StrengthenRNATechnology Layout
On October 10, 2025, Bristol-Myers Squibb (BMS) announced the acquisition of Orbital Therapeutics for $1.5 billion in cash. Orbital focuses on next-generation RNA therapeutics, with its lead candidate OTX-201 being an in vivo CAR-T therapy that delivers circular RNA via lipid nanoparticles (LNP), targeting CD19 for autoimmune diseases. BMS will also gain access to Orbital’s integrated platform technology encompassing circular RNA, LNP delivery, and AI-driven design. (Source: BMS Official Website)
KiteAuthorization and Cooperation Agreement with PreGen Reached
Following8Following the acquisition of Interius in August, Kite further reached a global collaboration with Pregene Biopharma Co., Ltd. (Pregene) in Shenzhen, China, on October 16, 2025, signing a licensing and collaboration agreement to support and accelerate the development of next-generation in-situ editing therapies. According to the agreement, Pregene will integrate its high-throughput drug optimization platform and manufacturing processes with Kite.KiteJointly optimize the path from early detection to clinical development. (Source: PreGen Official Website)
Nona BiosciencesAndUmoja BiopharmaExpand Cooperation
On November 5, 2025, Nona Biosciences announced the expansion of its strategic partnership with Umoja Biopharma. The collaboration will leverage Nona’s proprietary HCAb Harbour Mice and NonaCarFx.®The platform, together with Umoja's VivoVec™ platform, will co-create multiple in vivo CAR-T cell products to accelerate the development of next-generation therapies. (Source: Nona Official Website)
Empowering In Vivo CAR-T Development: Protein Solutions
ACROBiosystems is committed to combining its superior products with cutting-edge technology to provide comprehensive support for the development of In Vivo CAR-T cell therapy. As a professional protein supplier in the pharmaceutical R&D field, based onStar StainingNew Generation Site-Specific Labeling Technology Platform，We have developed a variety of fluorescently labeled protein products,IncludingCD4、CD8、CD7、CD3、CD5etc.,Can be used for precise detection of antibody density in antibody-conjugated LNP (Ab-LNP), withStrong stability and good batch-to-batch consistencyAnd other characteristics, and provideMultiple Fluorescent Labeling TypesAnd the配套 flow cytometry detection solution fully supports the optimization and quality control needs of Ab-LNP antibody density.
Quantitative Analysis of Antibody-Conjugated LNP
Using a new generation of site-specific labeling technology to maintain the natural conformation of proteins;
Activity is not affected by labeling;
Stable labeling with high sensitivity and high specificity, validated by flow cytometry batch testing;
High batch-to-batch consistency.
Alexa Fluor™ 488-Labeled Human CD8 alpha Protein, His Tag（CDA-HA2H6）
?Ready-to-use design, providing flow cytometry validation data at various concentrations
1e5 of Mouse Anti-CD8 antibody coupled beads (5.5 μm) were stained with different concentration of Alexa Fluor 488-Labeled Human CD8 alpha Protein, His Tag (Cat. No. CDA-HA2H6) and negative control protein respectively, AF488 signal was used to evaluate the binding activity (QC tested).
?Binding activity is not affected by labeling.
1e5 of Mouse Anti-CD8 antibody coupled beads (5.5 μm) were stained with different concentration of Alexa Fluor 488-Labeled Human CD8 alpha Protein, His Tag (Cat. No. CDA-HA2H6) and negative control protein respectively, AF488 signal was used to evaluate the binding activity (QC tested).
?High Stability
Binding activity of three different lots of Alexa Fluor 488-Labeled Human CD8 alpha Protein, His Tag against Mouse Anti-CD8 antibody coupled beads (5.5 μm) was evaluated by flow cytometry. The result shows very high batch-to-batch consistency.
| Catalog Number | Product Name |
Alexa Fluor™ 488-Labeled Human CD3 epsilon Protein, His Tag | |
| Alexa Fluor™ 488-Labeled Human CD3 epsilon & CD3 delta Heterodimer Protein, His Tag&Tag FreeStar Staining | |
| Alexa Fluor™ 488-Labeled Human CD5 Protein, His TagStar Staining | |
| Alexa Fluor™ 647-Labeled Human CD5 Protein, His TagStar Staining | |
| Alexa Fluor™ 488-Labeled Human CD8 alpha Protein, His TagStar Staining | |
| Alexa Fluor™ 647-Labeled Human CD8 alpha Protein, His TagStar Staining | |
| Alexa Fluor™ 488-Labeled Human CD7 Protein, His TagStar Staining | |
| Alexa Fluor™ 647-Labeled Human CD7 Protein, His TagStar Staining | |
| Alexa Fluor™ 488-Labeled Human CD4 Protein, His TagStar Staining | |
| Alexa Fluor™ 647-Labeled Human CD4 Protein, His TagStar Staining |
Relevant Quality Control Reagent Kits
ACROBiosystems
inquiry@acrobiosystems.com
15117918562
(Note: Name + Company)